In contrast, other chronic peritoneal dialysis animal models showed that SGLT2 inhibitors improved peritoneal fibrosis and function (Zhou et al., 2019; Balzer et al., 2020; Shentu et al., 2021). This evidence concerns the gene SLC5A2 and Peritoneal Fibrosis.